Phase 2 N=1 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Ectropion · Skin Neoplasms
Primary: Graft Size Change — 10 percent change in graft
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=18 Fractional Ablative Laser Treatment for Skin Grafts
Burn Scar · Skin Graft Scar
Primary: Contracture of Scar Surface Area (Percentage of Original Area) — 97; 97 percentage
Phase 2 N=15 StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects
Third Degree Burn · Burns · Wound Infection
Primary: Percent Autograft Take on Wounds Prepared by StrataGraft™ Skin Tissue. — 97.7; 96.7 Percent Area of Autograft Take (%)
N/A N=130 RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction
Full-thickness Skin Defects · Degloving Injuries · Crush Injuries
Primary: Incidence of Treatment Area Healing — 30; 34 Treatment Areas — p=.005
N/A N=44 Epidermal Grafting in Wound Healing
Ulcer · Skin Ulcer · Wounds and Injuries
Primary: Number of Wounds With Complete Healing — 9; 13; 16; 20 number of wounds — p=0.366
Phase 1 N=30 StrataGraft® Skin Tissue as an Alternative to Autografting Deep Partial-Thickness Burns
Skin Wound · Burns · Trauma-related Wound
Primary: Number of Participants With Wound Closure of the Treatment Sites at Three Months — 29; 29 Participants
Phase 3 N=52 StrataGraft® Skin Tissue Expanded Access at Specific Study Sites ( StrataCAT )
Deep Partial-thickness Burn
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 46 Participants
N/A N=32 Split Thickness Donor Site Healing With MIST Study
Burns · Trauma · Venous Ulcers
Primary: Rate of Wound Healing — 12.1; 21.3 Days
N/A N=20 Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites
Surgical Wound
Primary: Progression of Wound Healing — 69.9; 75.6 percentage of skin graft take
N/A N=30 ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority) — 24; 22; 2; 4 Participants
N/A N=8 An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
Donor Site Complication
Primary: Percentage of Participants Who Had > 95 % Epithelialization at Day 10 — 0 percentage of participants
Phase 3 N=1 StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects
Skin Wound · Burns · Trauma-related Wound
Primary: Percentage of Participants Who Achieved Confirmed Complete Closure of StrataGraft Treatment Sites Without Autograft Within 12 Weeks of StrataGraft Application — 100…
N/A N=34 Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Epidermolysis Bullosa
Primary: Percentage of Grafts Successfully Treated — 78 Percentage of grafts
Phase 3 N=71 StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements
Burn, Thermal
Primary: Percent Area of Treatment Sites Requiring Autografting by Month 3 — 4.33; 102.10 percentage of treatment sites — p=<0.0001
Phase 3 N=112 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSG-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -0.8 days — p==0.0232
Phase 3 N=537 Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Venous Leg Ulcer
Primary: Complete Healing of the Study Ulcer by Week 16. — 201; 176 participants — p=0.1030
Phase 2 N=40 TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Phase 4 N=74 Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
Pain, Postoperative · Burns
Primary: A Measurement of Post Operative Pain Involving Skin Graft Donor Site Using Visual Analog Scale (VAS) Ranging 0-10, at 8 Hours Post-operatively — 3.14; 3.68; 3.67 score…
Phase 2 N=30 Clinical Study on Silk Sericin Wound Dressing for Split-thickness Skin Graft Donor Sites Treatment
Late Complication From Skin Graft · Infection of Skin Donor Site · Impaired Wound Healing
Primary: Clinical Efficacy of Wound Dressing Containing Silk Sericin for Split-thickness Skin Graft Donor Site Treatment — 12 Days
N/A N=9 Repair of Infective Wound Associated With Nerve Defect in the Finger Using A Bipedicled Nerve Flap
Infection Wound · Disruption of Nerve Repair
Primary: 2-point Discrimination Test — 7.5 mm
N/A N=101 A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries
Burns
Primary: Incidence of RECELL-treated Area Closure Compared to Control at 4 Weeks (Non-inferiority) — 82; 87; 82; 83 Participants
N/A N=25 A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
Burn Injury · Skin Graft
Primary: Part A: Number of Participants With Healing — 3; 21; 2; 22 Participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 3 N=107 Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)
Wounds
Primary: Intra-individual Difference in Time to Wound Closure — -1.4 days — p=<0.0001
N/A N=12 CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries
Burns
Primary: Number of Participants With Confirmed Treatment Area Closure of RECELL-treated Wounds Compared to Control (Non-inferiority) — 9; 9 Participants
Phase 2 N=20 Imatinib Mesylate to Treat Skin Changes in Patients With Chronic Graft-Versus-Host Disease
Sclerotic Graft Versus Host Disease · Imatinib Mesylate
Primary: Percent Change in Absolute Range of Motion (ROM) From Baseline to 6 Months — 94; 35; 16; 21 Percent change from baseline
N/A N=63 Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
Graft Versus Host Disease
Primary: CXCL10 in Skin — 273; 41; 7.5 Skin CXCL10 femtograms/micrograms — p=<0.01
Phase 4 N=43 Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts
Deep Partial Thickness Burn · Full Thickness Burns
Primary: VAS Score for Pain Before Dressing Removal — 11.0; 4.0 units on a scale
N/A N=44 Platelet-Rich Plasma (PRP) in Reconstructive Surgery on Children With Retractable Burn Sequelae on Extremities
Burns
Primary: Median Time Between Surgery Date and Start Date Compression. — 17; 19 day — p=>0.1574
Phase 2 N=7 Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa
Epidermolysis Bullosa Dystrophica · Epidermolysis Bullosa
Primary: Number of Wounds by Healing Category Per Investigator Visual Assessment — 35; 5; 2; 28 wounds